Correlations between lipoprotein(a) gene polymorphisms and calcific aortic valve disease and coronary heart disease in Han Chinese

Hongzhi Dong¹,², Hongliang Cong², Jing Wang³, Yiyao Jiang⁴,⁵, Chao Liu⁶, Yingyi Zhang², Yanbo Zhu⁷ and Qingtong Wang⁸

Abstract
Objective: To investigate the relationship between lipoprotein(a) gene (LPA) polymorphisms and calcific aortic valve disease (CAVD) and coronary heart disease (CHD) in Han Chinese.
Methods: A total of 148 patients were recruited (n = 71 with CAVD and n = 77 with CHD) based on a diagnosis achieved using color Doppler echocardiography, coronary angiography, or computed tomography angiography. Seventy-one control individuals without CAVD or CHD were also recruited. Biomarkers including levels of lipoprotein(a) [Lp(a)], low-density lipoprotein and high-density lipoprotein cholesterol, apolipoprotein A1, and apolipoprotein B were tested. LPA polymorphisms rs10455872, rs6415084, rs3798221, and rs7770628 were analyzed using SNaPshot SNP.

¹Graduate School, Tianjin Medical University, Tianjin, China
²Department of Cardiology, Tianjin Chest Hospital, Tianjin, China
³Department of Pathology, Tianjin Chest Hospital, Tianjin, China
⁴Department of Cardiovascular Surgery, The First Affiliated Hospital of Bengbu Medical College, Anhui, China
⁵Department of Cardiovascular Surgery, The First Central Hospital Affiliated to Nankai University, Tianjin, China
⁶Institution of Cardiovascular Disease, Tianjin Chest Hospital, Tianjin, China
⁷Department of Ultrasound, Tianjin Chest Hospital, Tianjin, China
⁸Department of Clinical Laboratory, Tianjin Chest Hospital, Tianjin, China

Corresponding author:
Hongliang Cong, Department of Cardiology, Tianjin Chest Hospital, Tianjin 300222, China.
Email: qingpinganes@aliyun.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Results: Lp(a) levels were significantly higher in CAVD and CHD groups compared with controls. There was no significant difference in the allelic frequency distribution of rs3798221, rs7770628, or rs6415084 between CHD, CAVD, and control groups. Linear regression showed that rs3798221, rs7770628, and rs6415084 were associated with increased Lp(a) concentrations. Two CAVD patients among the 219 participants carried AG minor alleles at rs10455872, while the remainder carried AA minor alleles.

Conclusion: rs3798221, rs6415084, and rs7770628 polymorphisms within LPA are associated with higher Lp(a) plasma levels, which correlate with increased CAVD and CHD risks.

Keywords
Lipoprotein(a) gene polymorphism, Han Chinese, calcific aortic valve disease, coronary heart disease, genotype, biomarker

Date received: 29 February 2020; accepted: 3 August 2020

Introduction
Epidemiological and genetic studies provide strong evidence that lipoprotein(a) (Lp(a)) is a causal risk factor for cardiovascular disease (CVD).\(^1\)\(^2\) Recent findings suggest that it is difficult to modify Lp(a) concentrations through lifestyle changes because levels are mainly determined by Lp(a) production rather than catabolism. Lp(a) levels are also highly heritable, with more than 50% of all variations caused by polymorphisms at the lipoprotein(a) gene (LPA) locus.\(^3\)\(^-\)\(^5\) LPA was sequenced in 1987,\(^6\) and since then several of its polymorphisms have been reported to be strong risk factors for CVD.

Lp(a) concentrations are particularly dependent on Apo A kringle-IV type 2 (KIV-2) copy numbers, with low KIV-2 copy numbers being associated with smaller Apo A isoforms and higher Lp (a) molar levels, leading to a higher risk of CVD.\(^7\) Furthermore, Lp(a) is a major carrier of pro-inflammatory and pro-calcifying oxidized phospholipids (OxPL), supporting an important role for OxPL-mediated valvular interstitial cell calcification in CVD development.\(^8\)\(^9\) rs10455872 is a common LPA single nucleotide polymorphism (SNP) that has been intensively studied,\(^10\) and which is significantly associated with Lp(a) concentrations in Caucasians. The minor allele (G; 7.0%) of rs10455872 is associated with increased Lp(a) levels.\(^11\) rs3798221, rs7770628, and rs6415084 SNPs in LPA have also been investigated,\(^12\)\(^-\)\(^14\) but these studies were mainly conducted in European Caucasian, African-American, or Hispanic-American populations; few studies have been carried out in the Han Chinese population.\(^15\) Therefore, this cross-sectional study aimed to assess the associations between Lp(a) levels and the four LPA SNPs, to determine whether they are linked to the risks of CAD or CAVD development in Han Chinese.

Methods

Study population
A total of 148 patients were recruited from the Department of Cardiology, Tianjin Chest Hospital between January 2017 and September 2018. They underwent an
echocardiographic assessment, coronary angiography (CAG), or computed tomographic angiography (CTA) and were divided into two groups: the CAVD group (n = 71, of whom 23 patients received CTA and 48 received CAG) including patients with aortic valve stenosis and without CHD, and the CHD group (n = 77, of whom 11 patients received CTA and 66 received CAG) including patients with CHD but without aortic valve stenosis. CAVD was defined by an echocardiographic assessment as increased echogenicity, calcification, and thickening ≥1 mm of the aortic valve, and trans-aortic valve flow velocity >2.5 m/s. CHD was defined as luminal diameter stenosis ≥50% in a major epicardial coronary artery and its main branch. The control group (n = 71 who all received CTA) was selected from the physical examination center during the same time period, and included individuals without CAVD or CHD but with an aortic jet velocity <1.5 m/s. Exclusion criteria for all participants were: aortic valve stenosis of rheumatic heart disease, infective endocarditis, severe renal failure, hyperparathyroidism, congenital bicuspid aortic valve, and lupus erythematosus.

The ethics committee of Tianjin Chest Hospital approved the study (approval no. 2019LW-008) and all study participants provide their written informed consent.

**Characteristics and lipid profile determination**

Characteristics such as age, sex, height, weight, body mass index (BMI), and blood pressure of each participant were recorded. After 12 hours of fasting, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), apolipoprotein A (Apo A), Apo B, triglycerides (TGs), and fasting blood glucose (FBG) were measured using commercial kits (Roche Diagnostics, Mannheim, Germany) and a Roche C701 analyzer. Information about participants’ history of diabetes and hypertension was obtained from the medical history.

**Lp(a) level determination**

Lp(a) levels were measured by the latex-enhanced immunoturbidimetric assay. The Lp(a) detection kit (Roche Diagnostics, Mannheim, Germany) was used to determine the precipitation at 800/660 nm using latex particles coated with an anti-Lp(a) antibody to allow agglutination with human lipoprotein. Lp(a) levels of less than 75 mmol/L were considered to be within the normal range.

**DNA extraction and genotyping**

Lp(a) concentrations were shown to be particularly dependent on KIV-2 copy number, which is determined by LPA. The NCBI dbSNP database was searched for LPA SNPs and rs10455872 (high frequency: A, low-frequency: G), rs3798221 (high frequency: G, low-frequency: T), rs6415084 (high frequency: C, low frequency: T), and rs7770628 (high frequency: T, low frequency: C) genotypes, which were shown to associate with CHD or CAVD in white European, African-American, and Hispanic-American cohorts. 10. Participants fasted for 12 hours, then 2 ml of peripheral whole blood was collected in ethylenediaminetetraacetic acid tubes, stored at −20°C and DNA was extracted using the phenol-chloroform method. rs10455872, rs3798221, rs6415084, and rs7770628 genotypes were determined using the SNpShot genotype discrimination assay. Genotyping was performed using the ABI PRISM® SNpShot™ Multiplex Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. Primer sequences are shown in Table 1.
Statistical analyses

Statistical analyses were performed using IBM SPSS software (version 22.0; IBM Inc., Armonk, NY, USA). The significance level was set at $P < 0.05$. Continuous variables (age, height, weight, and BMI) defined to follow a normal distribution were represented as means ± standard deviations, and compared using one-way analysis of variance. Those not following a normal distribution were represented as quartiles. Categorical data were reported as frequencies and percentages and compared using the Chi-square test. Indicators not following a normal distribution, such as Lp(a), underwent natural logarithm conversion and were compared using the Kruskal–Wallis test. Binary logistic regression was used to analyze the influence of different genotypes on the incidence of CAVD and CHD, and the odds ratio (OR) and 95% confidence interval (95% CI) were calculated. Linear regression was used to analyze the effects of different genotypes and APOB levels on the Lp(a) concentration, with a test level of $\alpha = 0.05$.

The four SNPs were also assessed for deviance from the Hardy–Weinberg equilibrium. Our results showed that there were no statistically significant differences between the actual genotype frequencies of the four SNPs and the expected value.

Results

Baseline characteristics and lipid profile level

Baseline characteristics. No significant differences were observed with respect to sex or BMI among the three groups; however, there was a significant difference in age ($P < 0.05$) with the average age of patients in the CHD group being significantly higher than that of control and CAVD groups. Alcohol consumption was not significantly different among the three groups, but there were significant differences in the history of diabetes and hypertension among the three groups ($P < 0.05$) (Table 2).

FBG and lipid profile level. Significant differences were found with respect to APOB and Lp(a) among the three groups, with LDL and FBG concentrations being significantly higher in CAVD and CHD groups compared with controls ($P < 0.05$). APOA and

---

Table 1. Primer sequences for PCR.

| Primer name | Primer sequence (5’ to 3’) | Product size (bp) |
|-------------|----------------------------|------------------|
| rs7770628-F | GAGTATTTTGAAATGCACCGTATG | 291              |
| rs7770628-R | CAGGCTAGAAACAAATATGCAGAAA|                 |
| rs3798221-F | AAAGCATGGGTCTTCTAACCATA  | 283              |
| rs3798221-R | TGGTTCTCTGCTCATGCAATTACT |                 |
| rs6415084-F | ACTCTCTGAGTCCCTACCATT    | 197              |
| rs6415084-R | TTAATAGCATGGATGGAGCTCA   |                 |
| rs10455872-F| CCTGAATGTGTAACCTCTCAGCA  | 245              |
| rs10455872-R| CATTCTAATCTCCAAGCCCTG    |                 |
| rs7770628-YS(F) | CTCCATGCACACTTTAATGTGA | 52               |
| rs3798221-YS(F) | GAGTTGGCCTTGGCTCTCTTTAT | 44               |
| rs6415084-YS(R) | TATACTCAGGAAAGAAGCCATGT | 56               |
| rs10455872-YS(F) | CAGACACCTTTGTCAGAACCACA | 61               |

F: forward primer R: reverse primer.
HDL concentrations were significantly lower in CAVD and CHD groups than controls ($P < 0.05$), but the TG concentration was significantly higher in the CHD group than in the control group ($P < 0.05$) (Table 2).

**SNP genotype distribution.** rs3798221, rs7770628, and rs6415084 were prevalent in our study, but rs10455872 was not. Of 219 participants, only two had AG minor alleles at rs10455872, and both were CAVD patients. The other 217 participants had AA minor alleles. Allelic frequencies of variants rs10455872(G), rs7770628(C), rs6415084(T), and rs3798221(T) were 0.005, 0.146, 0.126, and 0.422, respectively. There were no significant differences in genotypic or allelic frequencies among CAVD, CHD, and control groups (Table 3).

**SNP genotypes, Lp(a) levels, and their effects on CAVD and CHD.** Logistic regression analysis showed that there were no significant correlations between $LPA$ genetic variants (rs7770628, rs6415084, and rs3798221) and CAVD or CHD risk. However, there were significant positive associations between Lp(a) levels and the risks of CAVD and CHD, compared with the control group. Patients with hypertension had a significantly greater risk of CHD compared with controls ($P < 0.05$) (Table 4).

**Effects of LPA SNPs on Lp(a) concentrations in Han Chinese.** We next used linear regression analysis to test the association between Lp(a) levels and $LPA$ SNPs rs7770628, rs6415084, and rs3798221, adjusting for APOB levels. Positive associations between rs7770628, rs6415084, and Lp(a)
levels were observed. Participants with the rs7770628 CT/CC genotype had significantly higher Lp(a) concentrations than rs7770628 TT carriers, rs6415084 CT/TT carriers had significantly higher Lp(a) levels than those with the rs6415084 CC genotype, while participants with the rs3798221 GG/GT genotype had significantly higher Lp(a) levels than rs3798221 TT carriers (Table 5).

**Discussion**

CVD is the leading cause of death worldwide,\(^19\) and morbidity and mortality associated with CAVD and CHD are rising as a result of aging populations. CAVD affects 25% of individuals aged over 65 years and 50% of those above 85.\(^{20}\) There are currently no effective treatments for CAVD. Although there are many strategies for CHD prevention and treatment, cardiovascular events can still occur in individuals with well-controlled total cholesterol and LDL levels. Recently, an increasing body of evidence has identified high Lp(a) levels (>125 nmol/l or >50 mg/dl) as a causal and independent risk factor for CVD.\(^{21,22}\) A wide variation in Lp(a) levels among different ethnicities was observed by multiple studies. Similarly, we observed Lp(a) levels ranging from 2.0 to 504.2 nmol/L among

---

**Table 3. LPA SNP genotype and allele frequency distribution.**

| Subjects | All participants N=219 | Control group N=71 | CAVD group N=71 | CHD group N=77 | P value |
|----------|------------------------|--------------------|-----------------|----------------|---------|
| SNP ID   | Genotype               | No. (%)            | No. (%)         | No. (%)        | No. (%)  |
| rs7770628| TT                     | 161 (73.5)         | 54 (76.1)       | 53 (74.6)      | 54 (70.1) | 0.931   |
|          | CT                     | 52 (23.7)          | 15 (21.1)       | 16 (22.5)      | 21 (27.3) |         |
|          | CC                     | 6 (2.7)            | 2 (2.8)         | 2 (2.8)        | 2 (2.6)   |         |
|          | Allele                 |                    |                 |                |          |
|          | T                      | 374 (85.4)         | 123 (86.6)      | 122 (85.9)     | 129 (83.8) |         |
|          | C                      | 64 (14.6)          | 19 (13.4)       | 20 (14.1)      | 25 (16.2) |         |
| rs6415084| CC                     | 169 (77.2)         | 55 (77.5)       | 56 (78.9)      | 58 (75.3) | 0.968   |
|          | CT                     | 45 (20.5)          | 14 (19.7)       | 14 (19.7)      | 17 (22.1) |         |
|          | TT                     | 5 (2.3)            | 2 (2.8)         | 1 (1.4)        | 2 (2.6)   |         |
|          | Allele                 |                    |                 |                |          |
|          | C                      | 383 (87.4)         | 124 (87.3)      | 126 (88.7)     | 133 (86.4) |         |
|          | T                      | 55 (12.6)          | 18 (12.7)       | 16 (11.3)      | 21 (13.6) |         |
| rs10455872| AA                    | 217 (99.1)         | 71 (100)        | 69 (97.2)      | 77 (100)  | 0.122   |
|          | AG                    | 2 (0.9)            | 0 (0.0)         | 2 (2.8)        | 0 (0.0)   |         |
|          | Allele                |                      |                  |                |          |
|          | A                      | 436 (99.5)         | 142 (100)       | 140 (98.6)     | 154 (100) |         |
|          | G                      | 2 (0.5)            | 0 (0.0)         | 2 (1.4)        | 0 (0.0)   |         |
| rs3798221| GT                    | 107 (48.9)         | 35 (49.3)       | 35 (49.3)      | 37 (48.1) | 0.934   |
|          | GG                    | 73 (33.3)          | 25 (35.2)       | 24 (33.8)      | 24 (31.2) |         |
|          | TT                    | 39 (17.8)          | 11 (15.5)       | 12 (16.9)      | 16 (20.8) |         |
|          | Allele                |                      |                  |                |          |
|          | G                      | 253 (57.8)         | 85 (59.9)       | 83 (58.5)      | 85 (55.2) |         |
|          | T                      | 185 (42.2)         | 57 (40.1)       | 59 (41.5)      | 69 (44.8) |         |

SNP, single nucleotide polymorphism; CAVD, calcific aortic valve disease; CHD, cardiovascular disease.
219 participants. Our data also suggest that the risks of CAVD and CHD increase with rising Lp(a) concentrations, and that Lp(a) is an independent and strong risk factor for CVD in the Han Chinese population.

To date, most studies on rs10455872 have been conducted in European Caucasian, African-American, Hispanic-American, and South Asian populations, with few studies in Han Chinese. We observed only two carriers of rs10455872 AG minor alleles out of 219 participants; both were CAVD patients. In contrast, 217 participants carried AA minor alleles. The allelic frequency of rs10455872 (G) was 0.005, which suggests a notable difference between non-Chinese and Han Chinese populations that is also supported by the rs10455872G genotype having high homology and a low mutation rate in Han Chinese, unlike in other ethnicities.

Because of the low frequency of minor alleles at this locus, we could not determine whether this SNP is associated with CHD/CAVD development in Han Chinese. However, we also observed that the unique structure of Lp(a) may explain its role in lesion development. Despite the small size of Lp(a) and Apo A, which are covalently bound by a single disulfide bond, the heterogeneous structure of the LPA gene may explain the high risk of CHD/CAVD development in Han Chinese, unlike in other ethnicities.

We further investigated the association between rs7770628 and Lp(a) levels in a post-hoc analysis of a Chinese population. We found that rs7770628 was closely related to both Lp(a) levels and CHD/CAVD development. The allele frequencies of rs7770628 were 0.685 for TT, 0.038 for CT, and 0.277 for CC. The OR for CHD/CAVD development was 1.733 for CT/CC carriers compared to TT carriers.

The rs3798221 variant, located on chromosome 6q27, was also investigated. It contains 10 KIV subtypes, of which KIV-2 is the most important and has a wide variation in copy number. Large Apo A isoforms, which have high KIV-2 copy number, have been associated with CVD risk in European populations. In contrast, few studies have investigated the association between rs3798221 and CVD in Han Chinese. We observed an association between rs3798221 and Lp(a) levels, with a significant increase in Lp(a) levels for GG/GT carriers compared to TT carriers.

Table 4. LPA SNP genotype, Lp(a) level and their effects.

| Variant | Valuation | CAVD group and Control group OR (95% CI) | CHD group and Control group OR (95% CI) |
|---------|-----------|------------------------------------------|------------------------------------------|
| Age (years) 40–88 | 0.996 (0.956, 1.036) | 0.829 (0.749, 0.914) | 0.997 (0.958, 1.038) | 0.899 (0.862, 0.938) | 0.996 (0.957, 1.037) | 0.851 (0.814, 0.891) |
| Hypertension 0= No Hypertension | 1.839 (0.879, 3.845) | 0.106 (0.005, 0.514) | 0.120 (0.053, 0.273) | 0.110 (0.054, 0.226) | 1.816 (0.870, 3.791) | 0.112 (0.056, 0.226) |
| LP(a) ln 0.69–6.22 | 1.733 (1.212, 2.480) | 0.003 (0.000, 0.062) | 0.002 (0.000, 0.062) | 0.000 (0.000, 0.017) | 1.674 (1.193, 2.351) | 0.003 (0.000, 0.017) |
| rs7770628 0= TT; 1= CT/CC | 0.685 (0.292, 1.608) | 0.385 (0.169, 0.871) | – | – | 0.685 (1.249, 2.595) | 0.002 (0.000, 0.082) |
| rs6415084 0= CT/TT; 1= CC | – | 1.862 (0.754, 4.598) | 0.178 (0.078, 0.409) | – | 1.862 (0.754, 4.598) | 0.002 (0.000, 0.082) |
| rs3798221 0= TT; 1= GG/GT | – | – | 0.519 (0.378, 0.634) | 0.519 (0.378, 0.634) | – | 0.519 (0.378, 0.634) |

CAVD, calcific aortic valve disease; CHD, cardiovascular disease; OR, odds ratio; CI, confidence interval.
KIV copy numbers in several ethnicities. An inverse relationship between Lp(a) levels and KIV-2 copy number has been reported, and a low KIV-2 copy number was shown to be associated with CVD.

*LPA* has approximately 50 genotyped SNPs that vary among different ethnicities. Zewinger et al. found that an increased plasma concentration of Lp(a) and a carrier of minor alleles at rs10455872 were pertinent to elevated CHD severity, while the CHARGE consortium detected a significant association between rs10455872 and the appearance of aortic valve calcification through a genome-wide association study. A similar result was observed in white European, African-American, Hispanic-American, and independent Danish cohorts. Lp(a) concentrations are thought to be determined by *LPA* genotype, which would allow the prediction of CAVD development, and this was borne out by a prospective analysis in a large Swedish cohort.

The frequency of the G allele at rs10455872 was shown to be 7% in Caucasians and 2% in Iranian CAD patients; this latter study found no correlation between *LPA* variants and CAD. *LPA* rs3798221 was previously shown to be closely related to the occurrence of myocardial infarctions and Lp(a) levels in different sexes. Our data also suggest that rs3798221 and rs7770628 are pertinent to Lp(a) levels in Han Chinese, but there were no clear correlations with the risk of CAVD or CHD.

Genetic variation at *LPA* rs6415084 was previously observed in 517 Han Chinese CHD patients in 2013. Compared with rs6415084 CC carriers, CT/TT carriers were shown to have significantly higher Lp(a) concentrations. We similarly found that the minor alleles of rs6415084 were associated with a higher Lp(a) plasma concentration, but there was no clear correlation between minor alleles and the risk of CAVD or CHD.

Although rs6415084, rs3798221, and rs7770628 were linked to increased Lp(a) levels, we detected no significant associations between the three SNPs and the risk of CAVD or CHD in the Han Chinese population. When compared with the control group, the risk of CAVD or CHD increased with increasing Lp(a) concentrations, suggesting that Lp(a) is an independent risk factor for CVD in Han Chinese. We were, however, unable to confirm whether rs10455872 is linked to the risk of CAVD or CHD.

Our study has a number of limitations. First, we had a relatively small cohort and variation was only detected in four SNPs. A larger sample size is therefore needed to identify more *LPA* SNPs in the Han Chinese population. Further exploration of *LPA* SNP variants, KIV2 copy number, and the risk of CAVD and CHD is also warranted. Additionally, we plan to

### Table 5. The effect of LPA SNPs on serum Lp(a) levels in the Chinese Han population.

| Variant | Valuation | β (95% CI) | P value | β (95% CI) | P value | β (95% CI) | P value |
|---------|-----------|------------|---------|------------|---------|------------|---------|
| APOB    | 0.37–5.75 | 0.036     | 0.300   | 0.033      | 0.054   | 0.403      | 0.021   |
| rs7770628 (0.036, 0.700) | –         | (0.006, 0.672) | –        | (0.061, 0.744) | –       | –         |         |
| rs6415084 (0.413, 1.064) | –         | –         | 0.000   | –          | 0.427   | 0.000      | (0.113, 0.740) |
| rs3798221 (0.061, 0.744) | –         | –         | 0.000   | –          | 0.427   | 0.000      |         |

SNP: single nucleotide polymorphism; APOB: apolipoprotein B; CI: confidence interval.
establish cell models to explore the functions of the abovementioned loci. Second, our study was limited to a cross-sectional analysis of the Han Chinese population, so our findings should be confirmed in other ethnic groups. Finally, PCR is not currently available in many clinical contexts. However, its increased accessibility in many hospitals will favor mid- and low-level risk patient groups which can be closely followed-up and treated in a timely manner via minimally invasive procedures such as transcatheter aortic valve implantation.

Conclusions

Our data suggest differences between the Han Chinese population and Caucasians and other ethnicities with respect to \( LPA \) SNPs and the risk of CAVD and CHD. We found that CAVD and CHD risks are not linked to genetic variation in \( LPA \) at SNPs rs6415084, rs3798221, and rs7770628 despite the observed association between the three SNPs and an increased level of Lp (a). However, the association between CAVD/CHD risk and increased Lp(a) levels indicates that Lp(a) is an independent risk factor for CVD in the Han Chinese population.

Acknowledgements

The authors are grateful to the participants and to the entire team of this study. This study was supported by Tianjin Chest Hospital.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

This research received a grant from the Tianjin Commission of Science and Technology (16ZXMJSY00140) and from the Research Foundation of Tianjin Chest Hospital (2018XKC17).

ORCID iDs

Hongzhi Dong https://orcid.org/0000-0002-2268-0727
Hongliang Cong https://orcid.org/0000-0002-9310-556X

References

1. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. \textit{JAMA} 2009; 302: 412–423. DOI: 10.1001/jama.2009.1063.
2. Nsaibia MJ, Mahmut A, Boulanger MC, et al. Autotaxin interacts with lipoprotein (a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease. \textit{J Intern Med} 2016; 280: 509–517. DOI: 10.1111/joim.12519.
3. Brown WV, Moriarty PM, Remaley AT, et al. JCL Roundtable: Should we treat elevations in Lp(a)? \textit{J Clin Lipidol} 2016; 10: 215–224. DOI: 10.1016/j.jacl.2016.02.012.
4. Schmidt K, Kraft HG, Parson W, et al. Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon. \textit{Eur J Hum Genet} 2006; 14: 190–201. DOI: 10.1038/sj.ejhg.5201512.
5. Zekavat SM, Ruotsalainen S, Handsaker RE, et al. Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries. \textit{Nat Commun} 2018; 9: 2606. DOI: 10.1038/s41467-018-04668-w.
6. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. \textit{N Engl J Med} 2009; 361: 2518–2528. DOI: 10.1056/NEJMoa0902604.
7. Gudbjartsson DF, Thorgerirsson G, Sulem P, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. \textit{J Am Coll Cardiol} 2019; 74: 2982–2994. DOI: 10.1016/j.jacc.2019.10.019.
8. Perrot N, Theriault S, Dina C, et al. Genetic variation in LPA, calcific aortic valve stenosis in patients undergoing cardiac surgery, and familial risk of aortic valve microcalcification. *JAMA Cardiol* 2019; 4: 620–627. DOI: 10.1001/jamacardio.2019.1581.

9. Zheng KH, Tsimikas S, Pawade T, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. *J Am Coll Cardiol* 2019; 73: 2150–2162. DOI: 10.1016/j.jacc.2019.01.070.

10. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. *N Engl J Med* 2013; 368: 503–512. DOI: 10.1056/NEJMoa1109034.

11. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. *JAMA* 2009; 301: 2331–2339. DOI: 10.1001/jama.2009.801.

12. Mack S, Coassin S, Rueedi R, et al. A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms. *J Lipid Res* 2017; 58: 1834–1844. DOI: 10.1194/jlr.M076232.

13. Kronenberg F and Utermann G. Lipoprotein(a): resurrected by genetics. *J Intern Med* 2013; 273: 6–30. DOI: 10.1111/j.1365-2796.2012.02592.x.

14. Ronald J, Rajagopalan R, Cerrato F, et al. Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk. *Stroke* 2011; 42: 2–9. DOI: 10.1161/STROKEAHA.110.591230.

15. Chen HY, Dufresne L, Burr H, et al. Association of LPA variants with aortic stenosis: a large-scale study using diagnostic and procedural codes from electronic health records. *JAMA Cardiol* 2018; 3: 18–23. DOI: 10.1001/jamacardio.2017.4266.

16. Lee SR, Prasad A, Choi YS, et al. LPA gene, ethnicity, and cardiovascular events. *Circulation* 2017; 135: 251–263. DOI: 10.1161/CIRCULATIONAHA.116.024611.

17. Cao J, Steffen BT, Budoff M, et al. Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in white and black individuals: the multi-ethnic study of atherosclerosis. *Arterioscler Thromb Vasc Biol* 2016; 36: 1003–1009. DOI: 10.1161/ATVBAHA.115.306683.

18. Lanktree MB, Anand SS, Yusuf S, et al. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. *Circ Cardiovasc Genet* 2010; 3: 39–46. DOI: 10.1161/CIRCGENETICS.109.907642.

19. Writing Group M, Mozaffarian D, Benjamin EJ, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. *Circulation* 2016; 133: e38–e360. DOI: 10.1161/CIR.0000000000000350.

20. O’Brien KD. Epidemiology and genetics of calcific aortic valve disease. *J Investig Med* 2007; 55: 284–291. DOI: 10.2310/6650.2007.00010.

21. Waldeyer C, Makarova N, Zeller T, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. *Eur Heart J* 2017; 38: 2490–2498. DOI: 10.1093/eurheartj/ehx166.

22. Verbeek R, Boekholdt SM, Stoekenbroek RM, et al. Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. *J Lipid Res* 2016; 57: 697–705. DOI: 10.1194/jlr.P066258.

23. Kronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases. *Cardiovasc Drugs Ther* 2016; 30: 87–100. DOI: 10.1007/s10557-016-6648-3.

24. Chretien JP, Coresh J, Berthier-Schaad Y, et al. Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans. *J Med Genet* 2006; 43: 917–923. DOI: 10.1136/jmg.2006.042119.

25. Li ZG, Li G, Zhou YL, et al. Lack of association between lipoprotein(a) genetic variants and subsequent cardiovascular events in Chinese Han patients with coronary artery disease after percutaneous coronary intervention. *Lipids Health Dis* 2013; 12: 127. DOI: 10.1186/1476-511X-12-127.
26. Enkhmaa B, Anuurad E, Zhang W, et al. Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk. *Metab Syndr Relat Disord* 2011; 9: 411–418. DOI: 10.1089/met.2011.0026.

27. Scipione CA, Koschinsky ML and Boffa MB. Lipoprotein(a) in clinical practice: New perspectives from basic and translational science. *Crit Rev Clin Lab Sci* 2018; 55: 33–54. DOI: 10.1080/10408363.2017.1415866.

28. Borrelli MJ, Youssef A, Boffa MB, et al. New frontiers in Lp(a)-targeted therapies. *Trends Pharmacol Sci* 2019; 40: 212–225. DOI: 10.1016/j.tips.2019.01.004.

29. Melzer D, Perry JR, Hernandez D, et al. A genome-wide association study identifies protein quantitative trait loci (pQTLs). *PLoS Genet* 2008; 4: e1000072. DOI: 10.1371/journal.pgen.1000072.

30. Yahya R, Berk K, Verhoeven A, et al. Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype. *Atherosclerosis* 2019; 289: 201–205. DOI: 10.1016/j.atherosclerosis.2019.07.001.

31. Thanassoulis G. Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis. *J Lipid Res* 2016; 57: 917–924. DOI: 10.1194/jlr.R051870.

32. Nordestgaard BG and Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. *J Lipid Res* 2016; 57: 1953–1975. DOI: 10.1194/jlr.R071233.

33. Zewinger S, Kleber ME, Tragante V, et al. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. *Lancet Diabetes Endocrinol* 2017; 5: 534–543. DOI: 10.1016/S2213-8587(17)30096-7.

34. Kamstrup PR, Tybjaerg-Hansen A and Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. *J Am Coll Cardiol* 2014; 63: 470–477. DOI: 10.1016/j.jacc.2013.09.038.

35. Laschkolnig A, Kollerits B, Lamina C, et al. Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. *Cardiovasc Res* 2014; 103: 28–36. DOI: 10.1093/cvr/cvu107.

36. Rouhani B, Ghaederian SMH and Salehi Z. Investigation of LPA sequence variants rs6415084, rs3798220 with conventional coronary artery disease in Iranian CAD patients. *Hum Antibodies* 2019; 27: 99–104. DOI: 10.3233/HAB-180353.

37. Chow CK, Islam S, Bautista L, et al. Parental history and myocardial infarction risk across the world: the INTERHEART Study. *J Am Coll Cardiol* 2011; 57: 619–627. DOI: 10.1016/j.jacc.2010.07.054.

38. Yoshino S, Cilluffo R, Prasad M, et al. Sex-specific genetic variants are associated with coronary endothelial dysfunction. *J Am Heart Assoc* 2016; 5: e002544. DOI: 10.1161/JAHA.115.002544.